Deciphera Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation expense
Noncash lease expense
Acquired in-process research and development
Gain on disposal of equipment
Net amortization (accretion) of premiums (discounts) on marketable securities
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Other long-term assets
Accounts payable
Accrued expenses and other current liabilities
Income tax liabilities
Operating lease liabilities
Other long-term liabilities
Net cash flows used in operating activities
Cash flows from investing activities:
Purchases of marketable securities
Maturities of marketable securities
Sales of marketable securities
Purchases of property and equipment
Proceeds from sale of equipment
Acquired in-process research and development
Increase in restricted investments
Net cash flows provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from offerings of common stock, net of underwriting discounts and commissions
Proceeds from issuance of convertible preferred shares
Repayment of notes payable to related party
Proceeds from pre-funded warrants
Payments of public offering costs
Payments of convertible preferred share issuance costs
Proceeds from stock option exercises and employee stock purchase plan
Net cash flows provided by financing activities

Net (decrease) increase in cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash paid for interest
Addition of operating lease asset included in accrued expenses and other current liabilities
Amounts capitalized under build-to-suit lease transaction
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities
Retirement of assets
Conversion of convertible preferred shares into common stock
Unsettled exercise of stock options

Comments